Plexus Research has created one of the largest clinical trial network for healthcare products in South Australia targeting drugs, devices, and digital solutions (3D) for Australian and global companies. In less than a year, Plexus, through their parent company, GP Partners Australia, has grown its network and has covered the majority of the population in Adelaide.
Plexus Research has announced that its new board will be led by Roseanne Healy as the Chair, Tam C Nguyen as a non-executive Director and Suhit Anantula as the Executive Director and CEO. Roseanne brings to Plexus Research over 20 years of corporate experience on mergers, acquisitions, capital raising and turnarounds; informed by investment banking, venture capital and start-up roles over the course of her career.
Associate Professor Tam Nguyen has over 20 years of working in the healthcare, health and medical research environm
Suhit is an award-winning global strategic design leader with experience in working across Australia, Asia, Europe and the US.
“By connecting a diverse network of clinics, GPs and patient populations we can solve the number one key challenge in clinical trials – on time recruitment!” he said.
In his various roles he has worked in global multinationals like ADP, start-ups like Deeshaa, NFPs like TACSI, in the public sector, small business and a consultant across the world in various industries and organisations.
According to some estimates, about 80% of all non-COVID trials have stopped or interrupted in 2020. 2021 and 2022 sees a huge increase in clinical trials and Plexus aims to capture that opportunity.
COVID has created a larger need for digital healthcare products which is a $200B market globally. By providing a commercial and clinical path to market for startups Plexus creates value in this fast-growing market.
Join our mailing list to be on the front lines of healthcare , get exclusive content, and promos.